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Abstract 
Background: Childhood asthma is very prevalent and costs can be high, especially in severe disease. This study aimed to estimate the cost of asthma in Portuguese children and the variations by level of asthma control. 
Methods: A nationwide, population- and prevalence-based cost-of-illness study with a societal perspective was conducted. We measured direct and indirect costs using a bottom-up approach and a human capital method, respectively, for 208 children (<18 years), from two national repositories. Generalised linear modelling for analysis of asthma costs’ determinants and sensitivity analysis to assess uncertainty were performed. 
Results: The mean annualised asthma cost per child was €929.35 (95%CI, 809.65–1,061.11): €698.65 (95%CI, 600.88–798.27) for direct costs, and €230.70 (95%CI, 197.36–263.81) for indirect costs. Extrapolations for the Portuguese children amounted to €161,410,007.61 (95%CI, 140,620,769.55–184,293,968.55) for total costs. Direct costs represent 75.2% with the costliest domain (51.1% of total costs) being the healthcare service use: 20.7% for scheduled medical visits and 30.4% for acute asthma care – non-scheduled medical visits (7.9%, €12,766,203.20), emergency department visits (11.7%, €18,932,464.80) and hospitalisations (10.8%, €17,406,946.00). Children with partly controlled and uncontrolled asthma had higher mean costs per year (adjusted coefficients: 1.46 [95%CI, 1.12-1.90] and 2.25 [95%CI, 1.56-3.24], respectively). 
Conclusions: Costs of childhood asthma are high (0.9% of the healthcare expenditures in Portugal). Direct costs represented 3/4 of total costs, mainly related to the use of healthcare services for acute asthma care. Policies and interventions to improve asthma control and reduce acute use of healthcare services have the potential to reduce asthma costs.  
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Introduction Health economic studies are important to support decision-makers in defining health priorities (1-3). In light of the increasing healthcare costs and the consequent threat to the sustainability of healthcare systems, focus should be put in assessing the impact of chronic diseases, aiming to reduce their burden (4). As one of the most common chronic diseases in childhood, asthma should have reliable economic data available. In childhood asthma, important direct costs (diagnostic tests, medications, medical visits, hospitalisations or emergency admissions) and indirect costs (mainly caregivers’ loss of work days and transportation to healthcare services) are relevant and can be high, especially in severe disease (5). In 2002, Druss et al have quoted asthma as the 13th most expensive medical condition in the USA (6). In 2011, Barnett and Nurmagambetov used a regression-based method to estimate $56 billions of incremental costs in all-age asthmatic USA population, with a mean value of $3,259 per person/year (7). In the same year, Bravo et al estimated the cost of asthma in children younger than 15 years old, in Spain, to be €532 million, (€1,149 person/year) (5). In the same study, the costs within each category of asthma severity ranged from €403 for the mildest to €5,930 for the most severe (costs person/year). Even though other asthma economic studies have been conducted, there are few population based and comprehensive pediatric cost-of-illness studies (8). This study aimed to estimate the cost of childhood asthma in Portugal. Secondary aims were: 1) to describe direct and indirect costs, 2) to determine factors associated with costs, and 3) to assess costs according to the level of asthma control.  
Methods 
Study design and setting The Cost of Childhood Asthma in Portugal (CASCA project) was a Portuguese, nationwide, population- and prevalence-based, cost-of-illness study with a societal perspective. This project was reviewed and approved by the Ethics Committee of Centro Hospitalar de São João, Porto, Portugal. Informed consent was obtained from parent(s) or legal guardian(s).  
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attending primary public schools in a Portuguese city (Guimarães), in 2013. Questionnaires were similar in the both studies, however, data on diagnostic tests use were only available in the CED2013 study (questions used are presented in Table S1). When the selected participant was younger than 15 years old, the respondent was the usual and most knowledgeable caregiver. For the CASCA project we included 208 children with current asthma (CA): 98 (0- to 17-years old) from the INAsma Study and 110 (5- to 12-years old) from the CED2013 Study (Fig. S1). Participants and data collection are further described in supplementary material. Data collection of prices of healthcare services, diagnostic tests, medication, holding chambers, absenteeism, transportation and subsidies were performed in different sources and databases as described below and in supplementary material.   
Cost estimation methods Direct healthcare costs of childhood asthma were estimated using a bottom-up approach (person-based). The cost domains included in direct costs were: 1) healthcare services (scheduled medical visits, non-scheduled medical visits, emergency department visits and hospitalisations); 2) diagnostic tests (blood workouts, skin prick tests, spirometries and chest x-ray); and 3) treatment (asthma-specific medication, other asthma-related medication and medical devices). Databases and reports from the Portuguese Central Administration of Health System (Administração Central dos Serviços de Saúde) (11), the Ministry of Health (12) and the National Authority of Medicines and Health Products (Infarmed) (13) were used to achieve unitary costs (mean prices per medication dose are presented in Table S2). A mean usage scenario for each medication was achieved by consensus, in accordance with international guidelines (14), in case of parent/self-reported use of the corresponding medication (used scenarios are presented in Table S3). Indirect costs of childhood asthma were estimated using the human capital method. The cost domains included in indirect costs were: 1) absenteeism; 2) transportation and 3) subsidies because of asthma. Databases and reports from the National Statistics Institute (Instituto 
Nacional de Estatística) (15) and the Ministry of Social Security (16,17) were used to achieve unitary costs. 
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Definitions CA was defined as children that ‘ever had asthma’ plus at least one of the following: wheezing, awakening with breathlessness or having an asthma attack in the previous 12 months, or taking asthma medication at the time of the interview. Asthma control was defined according to GINA (14), and categorised into ‘controlled’, ‘partially controlled’ and ‘uncontrolled’. Definitions for other variables are described in supplementary material.  
Statistical analysis Statistical analysis was performed using SPSS version 23 (SPSS IBM, New York, NY, USA). General characteristics of the included participants were described using absolute and relative frequencies. Cost variables were all annualised and presented as mean and standard deviation (SD) or 95% confidence interval (95%CI), calculated using bootstrap methods because of their skewed distributions (18,19). For each cost item and domain, extrapolated estimates for the Portuguese population were calculated. Extrapolation estimates were based on a prevalence estimate of CA from the INAsma Study (8.4% [95%CI, 6.6-10.7]), corresponding to a total weighted population of 173,681 Portuguese children with CA (9). The factors associated with costs of childhood asthma and, specifically, differences in levels of asthma control, were assessed using mixed Poisson-gamma models. A p-value of <0.05 was considered statistically significant. We additionally used decision analytic modelling to perform univariate and multivariate deterministic sensitivity analysis, in order to evaluate how the uncertainty would impact the estimates of national annualised costs of childhood asthma in Portugal. Univariate deterministic sensitivity analysis was performed with the 95%CI of the proportion estimates of occurrence of each item in Portuguese population. The multivariate deterministic sensitivity analysis was set with two case scenarios. The best-/worst-case scenario were set, respectively, with: the lower/upper limit of the 95%CI of CA prevalence in Portuguese children; scenario of minimum/maximum use of asthma medications (Table S3); and the lower/upper limit of the 95%CI for the proportion of occurrence of each item in Portuguese population.  
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Direct costs represented 75% and indirect costs 25% of the total costs. The most expensive domain was healthcare services use (€82,519,684.10; 51% of total costs), specifically scheduled medical visits (€33,414,070.10; 21% of total costs) and medical visits related to acute asthma care (€49,105,614.06; 30% of total costs): which encompassed non-scheduled medical visits (€12,766,203.20), emergency department visits (€18,932,464.80) and hospitalisations (€17,406,946.00).  
Factors associated with costs of asthma We observed significant crude associations between total annualised costs of childhood asthma and nocturnal symptoms, asthma attacks and level of asthma control (Table 2). However, only asthma attacks and level of asthma control had significant and independent associations with total annualised costs of childhood asthma in the final multivariate model adjusted for age. Children with asthma attacks in the previous 12 months had higher costs than those without asthma attacks (adjusted exponential model coefficients: 1.57 [95%CI, 1.22-2.02]). Children with partly controlled asthma and uncontrolled asthma had higher mean costs per year with adjusted exponential model coefficients of 1.46 [95%CI, 1.12-1.90] and 2.25 [95%CI, 1.56-3.24], respectively. The mean annualised costs per asthmatic child were €747.63 in those with controlled asthma, €1,120.50 in partly controlled and €1,758.44 in uncontrolled (p<0.001) (Fig. 1; Table S6). Total costs and direct costs, specifically healthcare services use by acute asthma care and diagnostic tests domains, were significantly higher in children with uncontrolled asthma (Fig. 2). Scheduled medical visits, treatment or indirect costs were not different between asthma control groups.  
Sensitivity analysis The univariate deterministic sensitivity analysis is presented in supplementary material (Table S7). The multivariate deterministic sensitivity analysis is presented in Table 3. The mean cost estimates per child with asthma varied between -35% and +53% for total costs, between -36 and +63% for direct costs, and between -30 and +23% for indirect costs. 
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Total, direct and indirect costs of childhood asthma The cost estimates for childhood asthma in Portugal were slightly lower than the Spanish estimates in 2008 (€1,149 child/year) (5); however, in this Spanish study the proportion of healthcare services use, diagnostic tests use, medication use and absenteeism because of childhood asthma were based on expert opinions; this could have overestimated these Spanish cost estimates. Otherwise, USA estimates for 2008 prices of 5- to 17-years old asthmatics were lower than ours: $791 child/year (direct costs, $401 child/year; indirect costs, $390 child/year) (21). In that study, the authors analysed data from the 1996 Medical Expenditure Panel Survey and the type of asthma-related expenditures used in direct costs were not clear. In Turkey, a study performed in 2006, in pediatric allergy and asthma referral centres, reported medical and non-medical costs of $1,597 per child/year (medical, $775; non-medical, $821), however, no formal indirect costs were reported (22). The definition of medical costs was similar to our definition of direct costs, and the results were also similar (assuming an 1.23 exchange rate of dollar to euro, in 2006). Non-medical costs included transportation (not absenteeism), but were mainly driven by non-allergic household measures ($710) like air filters, special vacuum cleaners or anti-allergic bed covers, that we did not assess in our study, as the current guidelines do not recommend them (14).  Previously published studies reported proportions of direct costs between 61-88% (8). Healthcare services use in the context of asthma worsening (non-scheduled medical visits, emergency and hospitalisations) were, altogether, 30% of the total costs of childhood asthma in Portugal. Reducing acute asthma care costs should be one of the major targets for potential savings. Also, by reducing it, other domains (e. g., indirect costs) could also be lowered as poor controlled asthma is associated to higher unscheduled medical visits and higher costs of lost work (10, 23). Indirect costs were one-fourth of the costs in childhood asthma. Other studies showed that indirect costs can be as high as 50% (8). The lack of assessment of costs related to presenteeism and lower salaries in Portugal may justify our proportion of indirect costs. Nevertheless, more than 13 million euros were spent yearly with parental absenteeism because of childhood asthma. This value can represent a potential higher burden to society, as loss of parental work can further impact the overall economy.  
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asthma control and reduce acute care medical visits. Other studies showed that asthma plans/interventions can reduce symptoms, reduce healthcare services use and be cost-effective (25, 26). Future studies should be designed to have multinational cost-of-illness data, aiming to understand differences between asthma care and to compare outcomes. Quality-of-life assessment in childhood asthma should also be improved and be part of a burden of disease analysis. 
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Table 1 Annualised costs (in euros) of childhood asthma in Portugal: total costs, mean cost per child with current asthma and percentage of total costs for each domain/variable. 
Table 2 Factors associated with annualised total costs of childhood asthma in Portugal. 
Table 3 Multivariate deterministic sensitivity analysis – Annualised total costs extrapolated to total Portuguese children with current asthma and mean costs per patient. 
Fig. 1 Mean annual costs per child with current asthma: Total mean annual costs and intervals according to the level of asthma control. Mean costs are marked in euros and the lines represent 95%CI. *p<0.001 between groups of asthma control. 




Total costs in Portuguese 
children* 
(95%CI#) 





TOTAL COSTS 161,410,007.61            (142,367,218.84 -181,369,857.87) 929.35                 (819.71 - 1,044.27) 100% 
DIRECT COSTS 121,341,498.02     (104,319,912.15 -139,851,241.14) 698.65                 (600.64 - 805.22) 75.2% 
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(9,809,363.94 - 15,874,252.35) (56.48 - 91.40)                 Emergency department visits 18,932,464.80 (13,136,536.12 - 26,300,288.04) 109.01 (75.64 - 151.43) 11.7%                  Hospitalisation 17,406,946.00 (6,189,712.95 – 30,072,795.68) 100.22 (35.64 - 173.15) 10.8% 
     Diagnostic tests 9,128,914.10 (7,988,735.48 - 10,293,812.35) 52.56 (46.00 - 59.27) 5.7%           Blood workout 2,498,121.71 (2,056,174.62 - 3,027,259.83) 14.38 (11.84 - 17.43) 1.5%           Chest x-ray 867,148.15 (726,594.46 - 1,012,508.13) 4.99 (4.18 - 5.83) 0.5%           Pulmonary function tests 4,840,864.14 (4,047,079.93 - 5,594,160.80) 27.87 (23.30 - 32.21) 3.0%           Skin prick tests 922,780.11 (787,921.22 - 1,060,409.35) 5.31 (4.54 - 6.11) 0.6% 
     Treatment 29,692,899.78 (26,638,427.58 - 32,734,734.89) 170.96 (153.38 - 188.48) 18.4% 
         Asthma-specific medication 16,005,602.20 (14,170,511.21 - 16,552,789.28) 92.16 (81.59 - 102.71) 9.9%                  Controller medication 14,731,639.10 (12,945,695.43 - 16,516,489.95) 84.82 (74.54 - 95.31) 9.1%                  Reliever medication 1,273,963.08(1,122,865.03 - 1,433,510.87) 7.34(6.47 - 8.25) 0.8% 
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(2,659,281.90 - 3,159,830.54) (15.31 - 18.19)
INDIRECT COSTS 40,068,509.59     (34,117,635.12 - 46,811,024.16) 230.70                 (196.44 - 269.52) 24.8% 
     Parental absenteeism 13,689,797.60 (10,775,047.66 - 16,906,907.47) 78.82 (62.04 - 97.34) 8.5% 
     Transportation 3,931,536.64 (3,397,478.25 - 4,553,290.57) 22.64 (19.56 - 26.22) 2.4% 
     Subsidies 22,447.175.39(17,551,402.93 - 27,735,327.31) 129.24(101.06 - 159.69) 13.9% Each cost item was calculated for each participant by multiplying the parent/self-reported amount of resources used by the unitary costs of the resources. Costs were indexed to 2010 Portuguese prices in euros. *Total costs were extrapolated to total Portuguese children with current asthma (n=173,681)(9);#Bootstrapped 95% confidence interval; n.a, not applicable †Mean cost per patient: sum of the total cost of each participant, dividing for the total number of asthmatic children in our sample.  
Table 2 
 Mean cost (SD) 






Gender         Female 999.44  (1,155.01)           1.00            (ref) n.i.      Male 888.99     (806.34) 0.89  (0.67-1.18) n.i. 
Age groups          0- 5 years old 1,035.91  (1,146.11)            1.00           (ref)        1.00             (ref)        6-12 years old 969.84     (974.54) 0.94 (0.60-1.46)   0.86  (0.59 -1.26)      13-17 years old 681.33     (618.04) 0.66 (0.39-1.14)   0.64  (0.40-1.03)
Caregiver education       No education 1,190.65  (1,311.41)           1.00            (ref) n.i.      0-4 years (basic 1st cycle) 1,011.55  (1,151.59) 0.85  (0.49-1.47) n.i.      5-9 years (basic 2nd and 3rd cycle) 1,010.83  (1,136.31) 0.85  (0.51-1.42) n.i.      10-12 years (secondary) 669.32     (442.65) 0.56  (0.32-1.01) n.i.      >12 years (higher) 840.07     (477.72) 0.71  (0.41-1.21) n.i. 
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     750.00 – 1,199.99€ 839.60     (972.68) 0.79  (0.52-1.21) n.i.      >= 1,200.00 € 755.10     (550.96) 0.71  (0.50-1.02) n.i. 
Wheezing       No 776.19     (746.83)          1.00             (ref) n.i.      Yes 964.25     (985.50) 1.24   (0.84-1.83) n.i. 
Nocturnal symptoms       No 685.41     (588.66)          1.00             (ref) n.i.      Yes 1,014.00  (1,034.80) 1.48  (1.07-2.05) n.i. 
Asthma attacks       No 677.58     (713.02)          1.00             (ref)       1.00              (ref)      Yes 1,136.82  (1,058.60) 1.68  (1.27-2.22) 1.57  (1.22-2.02)
Asthma control       Controlled 747.63     (562.79)          1.00             (ref)       1.00              (ref)      Partly controlled 1,120.50  (1,135.96) 1.50  (1.14-1.98) 1.46  (1.12-1.90)      Uncontrolled 1,758.44  (1,795.65)          2.35  (1.60-3.47)  2.25  (1.56-3.24)SD: standard deviation. 95%CI: 95% confidence interval. Bold values show statistical significant differences. n.i.: not included in the model (non-significant variables) *Adjusted coefficients were calculated using multivariate mixed Poisson-gamma (Tweedie distribution family) generalised linear models. Goodness-of-fit statistics for the multivariate regression model: scaled deviance (D = 2,919.3; df = 181); scaled Pearson chi-square (v2 = 181.0; df = 181); AIC = 5,111.3; consistent AIC = 5,136.7   
Table 3 
 Costs in Portuguese childhood asthma 
Multivariate sensitivity analysis 
Best-case scenario* Worst-case scenario# 
TOTAL COSTS 161,410,007.61     
(929.35) 
79,585,960.00    
(606.99) 
308,018,952.55    
(1,424.38) 
DIRECT COSTS 121,341,498.02     
(698.65) 
58,535,047.13    
(446.44) 
246,538,052.49     
(1,140.07) 
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                 Emergency department visits 18,932,464.80(109.01) 10,627,732.56(81.06) 29,012,394.70(134.16)                  Hospitalisation 17,406,946.00 (100.22) 2,628,165.12 (20.04) 43,346,333.38 (200.45) 





(66.99)           Blood workout 2,498,121.71 (14.38) 1,305,608.05 (9.96) 4,067,419.36 (18.81)           Chest x-ray 867,148.15 (4.99) 458,238.33 (3.49) 1,403,577.64 (6.49)           Pulmonary function tests 4,840,864.14(27.87) 2,626,641.61(20.03) 7,722,475.88 (35.71)           Skin prick tests 922,780.11 (5.31) 609,545.80 (4.65) 1,292,559.47 (5.98) 






         Asthma-specific medication 16,005,602.20 (92.16) 3,225,956.01 (24.60) 67,162,295.84 (310.58)                  Controller medication 14,731,639.10(84.82) 2,883,526.64(21.99) 63,387,483.49(293.12)                  Reliever medication 1,273,963.08 (7.34) 342,429.37 (2.61) 3,774,812.35 (17.46) 










This article is protected by copyright. All rights reserved. 
(16.69) (14.44) (19.18) 
INDIRECT COSTS 40,068,509.59        
(230.70) 
21,050,912.88     
(160.55) 
61,480,900.06     
(284.31) 
     Parental absenteeism 13,689,797.60 (78.82) 8,312,678.55 (63.40) 20,379,882.34 (94.24) 
     Transportation 3,931,536.64 (22.64) 2,770,123.76 (21.13) 5,221,446.58 (24.15) 
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